Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Opus GeneticsIRD -0.30%24 3-1 Month Momentum % is -29.39% as of Jul. 19, 2026. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.36 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,387 Biotechnology companies, Opus Genetics ranks worse than 77.87% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-19), Opus Genetics's 3-1 Month Momentum % is -29.39%.
The industry rank for Opus Genetics's 3-1 Month Momentum % or its related term are showing as below:
IRD's 3-1 Month Momentum % is ranked worse than 77.87% of 1387
companies
in the Biotechnology industry
Industry Median: -13.58
vs IRD: -29.39
Opus Genetics (NAS:IRD) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Opus Genetics 3-1 Month Momentum % Related Terms
IRD vs PALI, VSTM, GALT: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Opus Genetics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Opus Genetics's 3-1 Month Momentum % falls into.
Opus Genetics (NAS:IRD) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics (IRD) has a 3-1 Month Momentum % of -29.39% as of Jul. 19, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Opus Genetics and its competitors. According to the industry distribution chart, Opus Genetics ranks #1080 out of 1387 companies in the Biotechnology industry, placing it in the top 77.9%.
Is Opus Genetics' 3-1 Month Momentum % too high?
Opus Genetics' current 3-1 Month Momentum % is -29.39%. Based on the distribution chart, Opus Genetics ranks #1080 out of 1387 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' 3-1 Month Momentum % compare to PALI and VSTM?
According to the Biotechnology industry distribution chart, Opus Genetics ranks #1080 out of 1387 companies for 3-1 Month Momentum %. This places Opus Genetics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Opus Genetics and its competitors. Opus Genetics's current 3-1 Month Momentum % is -29.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.36, compared to a current price of $3.26 — trading 805.6% above its estimated fair value. The current 3-1 Month Momentum % is -29.39%. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Opus Genetics (IRD), the current 3-1 Month Momentum % is -29.39% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Opus Genetics (IRD) Overvalued in 2026?
Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued.
The current stock price of $3.26 is trading 805.6% above its estimated GF Value™ of $0.36.
GuruFocus considers Opus Genetics to be Significantly Overvalued.
Key valuation signals for IRD:
3-1 Month Momentum %: -29.39%
GF Value™: $0.36 vs. price of $3.26 (805.6% above fair value)
No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score
Get the complete analysis for IRD
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRD has been successfully added to your 
